康辰藥業(603590.SH):KC1036治療12歲及以上青少年晚期尤文肉瘤Ⅱ期臨牀研究完成首例受試者入組
格隆匯2月14日丨康辰藥業(603590.SH)公佈,公司自主研發的KC1036片(簡稱“KC1036”),順利完成“評價KC1036治療12歲及以上青少年晚期尤文肉瘤患者的安全性、有效性和藥代動力學的Ⅱ期臨牀研究(KC1036-PED-01)”首例受試者入組服藥。截止信息發佈之前,受試者安全性良好。
KC1036是公司自主研發的化學藥品1.1類創新藥,公司擁有該產品的全球知識產權。KC1036通過抑制VEGFR2、AXL等多靶點實現抗腫瘤活性。KC1036具有較強的VEGFR血管靶向,抑制腫瘤細胞生長;通過抑制AXL,可以改善宿主的抗腫瘤免疫應答,從而避免腫瘤的免疫逃逸。
目前KC1036針對成人消化系統腫瘤、胸腺腫瘤等多個適應症正在開展臨牀研究,截至目前,已有近300例受試者入組KC1036臨牀研究,現有臨牀研究結果顯示了突出的抗腫瘤活性、以及良好的安全性和耐受性。這爲KC1036開展青少年實體腫瘤臨牀研究提供有力的支持性證據。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.